Mauna Kea looks to raise $67.7M in IPO

France's Mauna Kea Technologies, which makes the world's smallest microscope used to examine the inside of the human body, is hoping to raise about $67.7 million from its initial public offering. As Reuters notes, the company is moving ahead with its plans even though more than 15 European IPO deals have failed this year, including Agendia, a Dutch maker of breast cancer tests, and Verallia, Saint-Gobain's glass container unit. Mauna Kea, which is set to list on the NYSE Euronext, said the price range of its IPO would be between €10.65 and €13 a share and that the offer would close July 4. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.